Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study)
Purpose of the article: Interleukin-23 inhibitors, such as tildrakizumab, have emerged as safe and effective options for the management of psoriasis. Yet their efficacy in elderly patients (aged 65 years or more), particularly in those with difficult-to-treat areas involvement, remains insufficientl...
Spremljeno u:
Glavni autori: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Knjiga |
Izdano: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Teme: | |
Online pristup: | Connect to this object online. |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Internet
Connect to this object online.3rd Floor Main Library
Signatura: |
A1234.567 |
---|---|
Primjerak 1 | Dostupno |